Status:
COMPLETED
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Lead Sponsor:
Federation Francophone de Cancerologie Digestive
Conditions:
Gastrointestinal Carcinoid Tumor
Islet Cell Tumor
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from ...
Detailed Description
OBJECTIVES: Primary * Determine the 6-month progression-free survival rate in patients with unresectable locally advanced or metastatic neuroendocrine tumors of the duodenum/pancreas treated with fl...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of neuroendocrine tumor of the duodenum/pancreas by histology or bone scan
- Functional or nonfunctional tumor
- Tumor meets ≥ 1 of the following criteria:
- Hepatic or extrahepatic metastases
- Progressive locally advanced tumor (primary or adenopathies)
- Unresectable disease
- Tumor differentiated and meets the following criteria:
- Ki 67 ≤ 15%
- Less than 10 mitoses per 10 large fields
- Measurable or evaluable disease
- Target lesions must meet 1 of the following criteria within the past 6 months:
- Increase of 20% in the longest diameter
- New metastases detected
- Minimum size of lesions must be 1 of the following:
- More than 15 mm for metastases
- More than 50 mm for primary tumor or local lymph nodes
- PATIENT CHARACTERISTICS:
- WHO performance status 0-2
- Creatinine ≤ 1.5 mg/dL
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Bilirubin ≤ 1.8 mg/dL
- No coronary insufficiency or symptomatic cardiac disease
- No intestinal obstruction, enteropathy, or uncontrolled chronic diarrhea
- No Gilbert's disease
- No psychological, social, familial, or geographic condition that would preclude study treatment
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 6 months after completion of study therapy
- No other condition that would preclude study therapy
- PRIOR CONCURRENT THERAPY:
- No prior adjuvant radiotherapy
- At least 3 months since prior interferon
- Prior somatostatin analogs or antisecretories allowed
- No other prior treatment for this cancer
- No concurrent radiotherapy to the target lesion
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00416767
Start Date
May 1 2004
End Date
July 1 2007
Last Update
May 30 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.